Global

CSL Behring Prof. Heimburger Award
Global Research Grant – Coagulation

CSL Behring is committed to supporting long-range progress in the area of coagulation. Based on recent publications and feedback from the medical community, it is important to encourage the next generation of coagulation specialists to medically and scientifically establish themselves, in order to have continued progress in this therapeutic area. CSL Behring will fund the fifth cycle of a global grant program to support the above objective.

Professor Dr. Norbert Heimburger


Professor Dr. Norbert Heimburger
Professor Dr. Norbert Heimburger, a CSL Behring employee for over three decades, devoted his work to blood coagulation. During that time, he characterized and purified a large number of plasma proteins and was instrumental in making these available to the medical community as therapeutic options. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization.

Due to his determination and his constant interaction with leading hemophilia and coagulation specialists, Behring launched the first effectively virus-inactivated FVIII concentrate in 1981. Honored with the Order of Merit of the Federal Republic of Germany in 1991, Professor Dr. Heimburger retired in 1991 but was still very much involved with CSL Behring as a Scientific Advisor until he passed away in September 2006.

CSL Behring named this grant CSL Behring - Prof. Heimburger Award to honor Professor Dr. Heimburger.

Funds Available

CSL Behring will set up five (5) global start-up grants of € 20.000 each for the 2012 cycle. No matching funding is a prerequisite for this grant. The grants will be available for preclinical and/or clinical research in the area of coagulation. 

Eligibility

The grants are targeted at investigators who hold an MD degree and have less than five years faculty experience in hemostasis.

To Apply

Apply in one of these ways:

 

CSL Behring GmbH
Att. Dieter Pluennecke
Commercial Development Coagulation
Emil-von-Behring-Strasse 76
35041 Marburg
GERMANY
T: +49 6421 394191
E-mail: Heimburger.Award@cslbehring.com

Applications — consisting of application form, current CV and research proposal (one-pager) — must be postmarked no later than 7 October 2011 to be considered for the next cycle. Applications should be submitted to the address above and can also be submitted via e-mail.

All applications will be forwarded to a selection committee consisting of four scientifically renowned clinicians in the field of coagulation:

Thomas Abshire, MD
Blood Center of Wisconsin,
Milwaukee, WI, USA

Prof. Dr. Barbara Zieger
Universitätsklinik Freiburg, Zentrum für
Kinderheilkunde, Freiburg, Germany

Claude Négrier, MD
Centre Régional de Traitement de L’Hemophilie,
Hopital Edouard Herriot, Lyon, France

Patricia Casais, MD
Academia Nacional de Medicina,
Fundacion de la Hemofilia, Buenos Aires, Argentina

The selection committee will review applications based solely on scientific merit. CSL Behring will notify the recipients in February 2012. The grants will be awarded at the CSL Behring-Prof. Heimburger Award Symposium in Marburg, Germany. All winners will be invited to present their supported projects to the Selection Committee. They will also meet previous winners and benefit from this global exchange platform for hemostasis among upcoming researchers.

More Information

Grant statutes are available by downloading Research Grant Statutes. Note: To view this document, you must have Adobe Acrobat Reader installed. Reader is available as a free download from Adobe Systems Inc.

Inquiries

For inquiries regarding applications, policy and procedures information, please contact:

CSL Behring GmbH
Att. Dieter Pluennecke
Commercial Development Coagulation
Emil-von-Behring-Strasse 76
35041 Marburg
GERMANY
T: +49 6421 394191
e-mail: heimburger.award@cslbehring.com

Decision Process

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia.